General
Preferred name
LENVATINIB
Synonyms
E7080 ()
E7080 (mesylate) ()
E7080, ER-203492-00, Lenvatinib Mesylate ()
E7080 (Lenvatinib) ()
A-13861 ()
E-7080 ()
6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]-amino]phenoxy]-7-methoxy- ()
LENVATINIB MESYLATE ()
Lenvatinib (mesylate) ()
ER-203492-00 ()
KISPLYX ()
LENVIMA ()
Lenvatinib (E7080) ()
Lenvatinib (E7080) Mesylate ()
E7080 mesylate ()
Lenvatinib-d4 ()
Lenvatinib methanesulfonate ()
Lenvatinib mesilate ()
E-7080 MESYLATE ()
P&D ID
PD003669
CAS
417716-92-8
857890-39-2
2264050-65-7
Tags
drug
natural product
available
Approved by
EMA
FDA
PMDA
First approval
2015
Drug indication
Non-small-cell lung cancer
Melanoma
Hepatocellular carcinoma
Renal cell carcinoma
Ovarian cancer
Solid tumour/cancer
Thyroid cancer
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION Lenvatinib is indicated for the treatment of following conditions.; ; - Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.; ; - Treatment of advanced renal cell carcinoma (RCC) in combination with everolimus following one prior antiangiogenic therapy.; ; - First-line treatment of unresectable hepatocellular carcinoma (HCC).
DESCRIPTION Lenvatinib is a potent inhibitor of VEGFR-2 (KDR) and VEGFR-3 (FLT4) . (GtoPdb)
DESCRIPTION inhibitor of VEGFRs, c-KIT, and PDGFR alpha and beta (Informer Set)
DESCRIPTION Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. (PKIDB)
Cell lines
1
Organisms
0
Compound Sets
26
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
Clinical kinase drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
Informer Set
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
External IDs
57
Properties
(calculated by RDKit )
Molecular Weight
426.11
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
3
cLogP
4.07
TPSA
115.57
Fraction CSP3
0.19
Chiral centers
0.0
Largest ring
6.0
QED
0.55
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
FLT1
FLT3
KDR
KIT
PDGFRA
PDGFRB
FGFR1
PDGFR??
VEGFR1/FLT1
VEGFR2/KDR
VEGFR3/FLT4
FLT4, KDR
RTK inhibitor
c-Kit
FGFR
PDGFR
RET
VEGFR
FLT4
FGFR2
FGFR3
FGFR4
c-Kit,c-RET,FGFR,PDGFR,VEGFR
Compound status
FDA
Targets
KDR,FLT4
Pathway
Angiogenesis
Tyrosine Kinase/Adaptors
Chromatin/Epigenetic
Protein Tyrosine Kinase/RTK
MOA
FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor
Indication
thyroid cancer
Source data